Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. S. Pullamsetti, E. Burghaüsen, S. Dabral, E. Butrous, A. Tretyn, R. Savai, H. A. Ghofrani, N. Weissmann, F. Grimminger, W. Seeger, S. Rosenkranz, R. T. Schermuly (Bad Nauheim, Giessen, Cologne, Germany; Kent, United Kingdom). PDGF and Src tyrosine kinases in pulmonary arterial smooth muscle cells: Effects of dasatinib and nilotinib on pulmonary vascular remodeling. Eur Respir J 2011; 38: Suppl. 55, 410

Member's Comments

No comment yet.

Related content which might interest you: Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Eur Respir Rev 2008; 17: 72-73 Year: 2008 FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl Source: Eur Respir J 2011; 37: 78-88 Year: 2011 Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation Source: ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019 Year: 2019 Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 MAP kinases mediate FGF-induced expression and release of VEGF in human airway smooth muscle cells: The role of azithromycin Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011 Role of adenylate kinase 4 as a new metabolic regulator of pulmonary artery smooth muscle cells under hypoxia Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Tyrosine kinase inhibition of human pulmonary fibroblast migration Source: Eur Respir J 2005; 26: Suppl. 49, 101s Year: 2005 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed Source: Eur Respir J 2013; 41: 3-4 Year: 2013 Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 The effect of ASK1 inhibition on hypoxia-induced pulmonary artery fibroblast activation and associated paracrine effects on vascular smooth muscle cells Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020 Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004 Bosentan stimulates the expression of cell cycle inhibitor p27(kip1) in pulmonary artery smooth muscle cells (PASMC) Source: Annual Congress 2007 - Animal and ex vivo models of airway inflammation Year: 2007 Endothelin-1 inhibits TASK-1 in human pulmonary artery smooth muscle cells via phospholipase C-diacylglycerol-protein kinase C-pathway Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 MAP kinase phosphatase 1 mediates glucocorticoid inhibition of CD38 expression in human airway smooth muscle Source: Annual Congress 2008 - Basic science in asthma and COPD II Year: 2008